Bernd C. Kieseier
#148,311
Most Influential Person Now
Bernd C. Kieseier's AcademicInfluence.com Rankings
Bernd C. Kieseierphilosophy Degrees
Philosophy
#8075
World Rank
#11388
Historical Rank
Logic
#5106
World Rank
#6470
Historical Rank
Bernd C. Kieseierbiology Degrees
Biology
#10907
World Rank
#14269
Historical Rank
Neuroscience
#1734
World Rank
#1788
Historical Rank
Download Badge
Philosophy Biology
Why Is Bernd C. Kieseier Influential?
(Suggest an Edit or Addition)Bernd C. Kieseier's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Defining the clinical course of multiple sclerosis (2014) (2372)
- Acute disseminated encephalomyelitis: an update. (2005) (340)
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis (2011) (318)
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study (2014) (306)
- The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis (2011) (279)
- Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis (2004) (278)
- Immunopathogenesis and immunotherapy of multiple sclerosis (2006) (269)
- The role of macrophages in immune-mediated damage to the peripheral nervous system (2001) (263)
- Assessing walking disability in multiple sclerosis (2012) (240)
- Clinical Relevance of Brain Volume Measures in Multiple Sclerosis (2014) (240)
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) (239)
- Statins as immunomodulators: Comparison with interferon-&bgr;1b in MS (2002) (222)
- Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system (2004) (201)
- The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. (2008) (198)
- Immunobiology of muscle: advances in understanding an immunological microenvironment. (2005) (192)
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
- Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. (2015) (185)
- The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system (2000) (175)
- Guillain-Barré syndrome after exposure to influenza virus. (2010) (175)
- Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. (1998) (173)
- Fingolimod is a potential novel therapy for multiple sclerosis (2010) (172)
- Chronic inflammatory demyelinating polyneuropathy. (2005) (165)
- Regional variation of Guillain-Barré syndrome (2018) (156)
- Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. (2005) (155)
- Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. (2005) (151)
- Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. (2002) (151)
- Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model (2015) (146)
- l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients (2013) (144)
- Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. (2003) (139)
- Acute disseminated encephalomyelitis: an acute hit against the brain (2007) (136)
- [Chronic inflammatory demyelinating polyneuropathy]. (2003) (136)
- Matrix metalloproteinases in inflammatory demyelination (1999) (136)
- Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. (2006) (129)
- Atacicept: targeting B cells in multiple sclerosis (2010) (123)
- Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? (2010) (117)
- Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. (2013) (115)
- From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve (2007) (106)
- Differential expression of matrix metalloproteinases in bacterial meningitis. (1999) (102)
- Expression of specific matrix metalloproteinases in inflammatory myopathies. (2001) (101)
- Matrix metalloproteinases MMP‐9 and MMP‐7 are expressed in experimental autoimmune neuritis and the guillain‐barré syndrome (1998) (99)
- Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis (2010) (99)
- Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE (2015) (97)
- Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. (2012) (96)
- Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis (2014) (96)
- CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system (2003) (95)
- Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis (2010) (94)
- Review of teriflunomide and its potential in the treatment of multiple sclerosis (2009) (91)
- Optimizing therapy early in multiple sclerosis: An evidence-based view. (2015) (91)
- Immune mechanisms in chronic inflammatory demyelinating neuropathy (2002) (91)
- Neurofilament ELISA validation. (2010) (90)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis (2005) (86)
- Fingolimod treatment promotes regulatory phenotype and function of B cells (2015) (85)
- Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice (2011) (84)
- Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model (2007) (82)
- Current disease-modifying therapies in multiple sclerosis. (2003) (81)
- Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. (2009) (81)
- Cytotoxic CD8+ T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death (2009) (80)
- Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy (2014) (78)
- Therapeutic role of mitoxantrone in multiple sclerosis. (2006) (77)
- Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients (2011) (77)
- Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. (2012) (75)
- Sequential expression of chemokines in experimental autoimmune neuritis (2000) (75)
- Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis (2005) (74)
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety (2015) (74)
- Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro (2005) (74)
- Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. (2002) (73)
- The immunocompetence of Schwann cells (2008) (73)
- Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod (2012) (73)
- Requirement for safety monitoring for approved multiple sclerosis therapies: an overview (2014) (71)
- Identification and development of new therapeutics for multiple sclerosis. (2008) (71)
- Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis (2007) (70)
- A critical appraisal of treatment decisions in multiple sclerosis—old versus new (2011) (69)
- Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b (2014) (69)
- Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy (2015) (69)
- Blood neurofilament light levels segregate treatment effects in multiple sclerosis (2020) (68)
- Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. (2006) (68)
- Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. (2007) (68)
- Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF (2015) (64)
- CIDP and other inflammatory neuropathies in diabetes — diagnosis and management (2017) (64)
- Effector pathways in immune mediated central nervous system demyelination. (1999) (64)
- alpha4-Integrin antagonism with natalizumab: effects and adverse effects. (2008) (63)
- Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. (1998) (62)
- ADAM‐10 and ADAM‐17 in the inflamed human CNS (2003) (61)
- Immune-mediated neuropathies (2018) (60)
- Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies (2006) (59)
- Neurofilament light levels are associated with long-term outcomes in multiple sclerosis (2019) (58)
- Changes to anti-JCV antibody levels in a Swedish national MS cohort (2013) (57)
- A role of peripheral myelin protein 2 in lipid homeostasis of myelinating schwann cells (2014) (57)
- Treatment and treatment trials in multiple sclerosis (2007) (55)
- Sural sparing pattern discriminates Guillain–Barré syndrome from its mimics (2014) (55)
- Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies (2010) (54)
- Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2016) (54)
- Recovery of the T-cell repertoire in CIDP by IV immunoglobulins (2013) (53)
- Immune circuitry in the peripheral nervous system (2006) (52)
- The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration (2011) (52)
- An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis (2010) (51)
- Progress in Guillain-Barré syndrome. (2001) (51)
- α4-Integrin antagonism with natalizumab (2008) (50)
- Matrix metalloproteinase‐2 is involved in myelination of dorsal root ganglia neurons (2009) (48)
- Neuromyelitis optica following human papillomavirus vaccination (2012) (48)
- Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum (2013) (48)
- PEGylation of Interferon-β-1a (2012) (47)
- Pharmacological Treatment of Early Multiple Sclerosis (2008) (46)
- CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus (2011) (46)
- Multiple sclerosis – novel insights and new therapeutic strategies (2005) (46)
- Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. (2009) (45)
- Review: Pathogenesis and treatment of immune-mediated neuropathies (2009) (45)
- Chronic inflammatory demyelinating polyneuropathy – update on pathogenesis, diagnostic criteria and therapy (2005) (44)
- Immunosuppressive agents in multiple sclerosis (2007) (44)
- Disease-Modifying Agents for Multiple Sclerosis (2012) (44)
- Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis (2009) (44)
- Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (2012) (44)
- Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis (2013) (43)
- PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease (2009) (43)
- Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis (2007) (43)
- Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. (2010) (42)
- Persistence of immunopathological and radiological traits in multiple sclerosis. (2008) (42)
- Recent developments and future directions in Guillain‐Barré syndrome (2012) (42)
- Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
- Alemtuzumab: the advantages and challenges of a novel therapy in MS. (2014) (42)
- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis (2014) (42)
- Expression and distribution of transcription factor NF-κB and inhibitor IκB in the inflamed peripheral nervous system (2001) (42)
- The clinical value of therapeutic plasma exchange in multifocal motor neuropathy (2008) (42)
- Tissue mRNA expression in rat of newly described matrix metalloproteinases. (2005) (41)
- Prion proteins: Physiological functions and role in neurological disorders (2008) (41)
- The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies (2007) (41)
- Development of oral cladribine for the treatment of multiple sclerosis (2010) (40)
- Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. (2006) (40)
- Biologic role of interferon beta in multiple sclerosis (2004) (40)
- Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. (2007) (38)
- Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II (2017) (37)
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies (2012) (37)
- Autoimmune diseases of the peripheral nervous system. (2012) (36)
- Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve (2003) (36)
- Erythropoietin Ameliorates Rat Experimental Autoimmune Neuritis by Inducing Transforming Growth Factor-Beta in Macrophages (2011) (36)
- Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. (2004) (36)
- Teriflunomide for the treatment of multiple sclerosis (2013) (36)
- Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany (2012) (35)
- Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results (2017) (34)
- Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) (2020) (34)
- Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis (2016) (34)
- Role of Nitric Oxide as Mediator of Nerve Injury in Inflammatory Neuropathies (2007) (34)
- Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation (2010) (34)
- Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies (2007) (33)
- Immunomodulatory treatment strategies in multiple sclerosis (2008) (33)
- A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany (2016) (32)
- Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies (2003) (32)
- Chemotherapeutics in the treatment of multiple sclerosis (2010) (32)
- Inflammatory Demyelinating Brain Lesions Heralding Primary CNS Lymphoma (2012) (31)
- Levetiracetam exhibits protective properties on rat Schwann cells in vitro (2011) (31)
- Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer (2012) (31)
- Oral Disease-Modifying Treatments for Multiple Sclerosis (2007) (31)
- Mechanisms of mitoxantrone in multiple sclerosis–what is known? (2004) (30)
- Incidence of Guillain‐Barré syndrome in Germany (2007) (30)
- Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
- Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. (2013) (30)
- IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) (2014) (29)
- Novel pathomechanisms in inflammatory neuropathies (2017) (29)
- New immunopathologic insights into multiple sclerosis (2003) (28)
- ‘Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis’ (2009) (28)
- Muscle-derived positive and negative regulators of the immune response (2005) (28)
- Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. (2011) (28)
- Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. (2010) (27)
- The future of multiple sclerosis therapy. (2009) (27)
- Multiple paradigm shifts in multiple sclerosis. (2003) (27)
- Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial (2016) (26)
- Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis (2015) (26)
- Involvement of ADAM10 in axonal outgrowth and myelination of the peripheral nerve (2009) (26)
- Immune regulation of multiple sclerosis. (2014) (26)
- Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. (2010) (25)
- Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS (2013) (25)
- Therapeutic strategies in the Guillain-Barré syndrome. (2003) (25)
- Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. (2001) (24)
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia (2014) (24)
- CME Statins as immunomodulators Comparison with interferon-1 b in MS (2002) (24)
- Mitoxantrone in multiple sclerosis. (2006) (24)
- Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. (2008) (23)
- Schwann cell-specific regulation of IL-1 and IL-1Ra during EAN: possible relevance for immune regulation at paranodal regions (2001) (23)
- Autoimmunity in the peripheral nervous system. (1996) (22)
- Treatment of active secondary progressive multiple sclerosis with treosulfan (2007) (22)
- Interleukin-17 impedes Schwann cell-mediated myelination (2014) (22)
- CD19 as a molecular target in CNS autoimmunity (2014) (21)
- Type III systemic allergic reaction to natalizumab. (2008) (21)
- TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis (2002) (21)
- Mitoxantrone (Novantrone®) in multiple sclerosis: new insights (2004) (21)
- Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab (2014) (21)
- An assay to quantify species-specific anti-JC virus antibody levels in MS patients (2013) (21)
- Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial (2017) (21)
- Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. (2006) (21)
- Interferon-β and neuroprotection in multiple sclerosis—Facts, hopes and phantasies (2007) (21)
- Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium (2020) (20)
- Risks and benefits of multiple sclerosis therapies: need for continual assessment? (2011) (20)
- Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling (2016) (20)
- Citalopram suppresses thymocyte cytokine production (2013) (19)
- Phagocytosis of apoptotic inflammatory cells downregulates microglial chemoattractive function and migration of encephalitogenic T cells (2006) (19)
- Translational research in neurology and neuroscience 2010: multiple sclerosis. (2010) (18)
- Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. (1998) (18)
- Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? (2012) (18)
- Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies (2016) (18)
- Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™. (2013) (18)
- The inflamed peripheral nervous system: update on immune therapies (2006) (18)
- How patients with multiple sclerosis acquire disability (2022) (18)
- FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies (2014) (18)
- A reliable in vitro model for studying peripheral nerve myelination in mouse (2013) (18)
- Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array (2015) (17)
- Isoniazid-induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping? (2015) (17)
- Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab (2008) (17)
- Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode (2020) (17)
- Anti-JC-virus antibody prevalence in a German MS cohort (2012) (16)
- Dimethyl fumarate alters intracellular Ca2+ handling in immune cells by redox-mediated pleiotropic effects. (2019) (16)
- Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. (2013) (16)
- Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. (2018) (16)
- Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes (2016) (16)
- Therapeutic Approaches to Multiple Sclerosis (2010) (16)
- Intravenous immunoglobulins in the treatment of immune neuropathies (2008) (16)
- Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis (2005) (16)
- Thymic Epithelium Determines a Spontaneous Chronic Neuritis in Icam1tm1JcgrNOD Mice (2014) (15)
- Review: Innovative monoclonal antibody therapies in multiple sclerosis (2008) (15)
- Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates (2015) (15)
- The Role of Peripheral Myelin Protein 2 in Remyelination (2018) (15)
- A patient with a benign course of neuromyelitis optica (Devic’s syndrome) over 12 years (2006) (15)
- Pregnancy Outcomes from the Teriflunomide Clinical Development Program: Retrospective Analysis of the Teriflunomide Clinical Trial Database (S30.005) (2013) (15)
- Cladribine as a therapeutic option in multiple sclerosis. (2012) (15)
- Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity (2013) (15)
- Tumor necrosis factor‐α‐converting enzyme is expressed in the inflamed peripheral nervous system (2005) (15)
- Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring (2020) (15)
- Defining a role for laquinimod in multiple sclerosis (2014) (15)
- Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis (2011) (14)
- [Revision of McDonald's new diagnostic criteria for multiple sclerosis]. (2006) (14)
- No blocking effects of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve (2003) (14)
- Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis (2005) (14)
- Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine (2010) (14)
- [Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]. (2005) (14)
- Charcot – Marie – Tooth disease CMT 4 A : GDAP 1 increases cellular glutathione and the mitochondrial membrane potential (2011) (14)
- Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway (2017) (14)
- Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia (2009) (14)
- Therapeutic Approaches to Multiple Sclerosis (2010) (14)
- Targets for the therapeutic action of interferon‐β in multiple sclerosis (1996) (13)
- Therapy of immune neuropathies with intravenous immunoglobulins (2006) (13)
- Assessing walking disability in multiple sclerosis.Mult Scler. 2012 Jul;18(7):914-24. doi: 10.1177/1352458512444498. Epub 2012 Apr 24. Review. (2012) (13)
- [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. (2011) (13)
- Novel treatment for immune neuropathies on the horizon (2011) (13)
- Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder (2015) (13)
- The monocyte-macrophage system is affected in lysosomal storage diseases: an immunoelectron microscopic study (1997) (13)
- Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner (2014) (12)
- The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis (2013) (12)
- Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation (2008) (12)
- Plasma exchange in immune-mediated neuropathies (2008) (12)
- Quinpramine Ameliorates Rat Experimental Autoimmune Neuritis and Redistributes MHC Class II Molecules (2011) (12)
- Promoting Myelination in an In Vitro Mouse Model of the Peripheral Nerve System: The Effect of Wine Ingredients (2013) (12)
- A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis (2020) (12)
- Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study (2019) (12)
- Autoantibody-mediated dysfunction of sympathetic neurons in guillain-barre syndrome. (2010) (12)
- Leukocytes in neuronal ceroid-lipofuscinoses: function and apoptosis (1997) (12)
- Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years (2022) (12)
- T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes (2013) (12)
- Updated Pregnancy Outcomes in Patients and Partners of Patients in the Teriflunomide Clinical Trial Program (P4.161) (2014) (12)
- Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide (2016) (11)
- Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy (2021) (11)
- Type III Systemic Allergic Reaction to Natalizumab. Authors' reply (2008) (11)
- Characterization of T–cell subclasses and NK–cells in lysosomal disorders by immuno–electron microscopy (1994) (11)
- Monomethylfumarate reduces in vitro migration of mononuclear cells (2014) (11)
- Differential impact of pure glyphosate and glyphosate-based herbicide in a model of peripheral nervous system myelination (2018) (11)
- No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis (2005) (11)
- Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies (2012) (11)
- Peripheral blood levels of matrix metalloproteinase-9 predict lesion volume in acute stroke (2013) (10)
- Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE (2017) (10)
- Quinpramine is a novel compound effective in ameliorating brain autoimmune disease (2009) (10)
- Chapter 27 – Experimental Autoimmune Neuritis (2005) (10)
- Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling (2020) (10)
- Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. (2010) (9)
- Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (2016) (9)
- Pregnancy Outcomes from the Teriflunomide Clinical Development Program: Retrospective Analysis of a Global Pharmacovigilance Database (P06.190) (2012) (9)
- Assessing long-term effects of disease-modifying drugs (2006) (9)
- Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis (2016) (9)
- Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA1 signaling (2018) (8)
- Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program (2014) (8)
- Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta (2017) (8)
- Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study (2014) (8)
- Bacteria and their cell wall components uniformly co‐activate interleukin‐17‐producing thymocytes (2014) (8)
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II (2022) (8)
- Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy (2010) (7)
- The Biology of Schwann Cells: Development, Differentiation, and Immunomodulation (2007) (7)
- Multiple sclerosis therapy: An update on recently finished trials (2007) (7)
- The CSF JCV antibody index for diagnosis of natalizumab-associated PML (2014) (7)
- Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide (2011) (6)
- Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System (2015) (6)
- CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve (2009) (6)
- Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards (2013) (6)
- Immunological surrogate markers of disease activity in multiple sclerosis. (1999) (6)
- Humoral immune responses after rabies infection. (2007) (6)
- Targeting two-pore domain potassium channels — A promising strategy for treating T cell mediated autoimmunity (2013) (6)
- Immunelectronmicroscopic characterization of T4 and T8 lymphocytes and natural killer cells in neuronal ceroid-lipofuscinosis. (1995) (6)
- Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis (2016) (6)
- The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives. (2014) (6)
- Normal superoxide radical production in the neuronal ceroid-lipofuscinoses. (1996) (6)
- Unilateral facial flushing and sweating after physical exercise: Harlequin syndrome. (2011) (6)
- [Targeting B cells in multiple sclerosis. Current concepts and strategies]. (2009) (5)
- ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133) (2012) (5)
- Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis (2022) (5)
- Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS (2021) (5)
- Trapped in the epineurium: early entry into the endoneurium is restricted to neuritogenic T cells in experimental autoimmune neuritis (2018) (5)
- Measuring treatment response to advance precision medicine for multiple sclerosis (2021) (5)
- [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system]. (2011) (5)
- Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS): Initial Launch Experience (P1.372) (2017) (5)
- Bacterial flagellin and diphtheria toxin co-stimulate IL-17-producing thymocytes. (2013) (5)
- Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006) (2013) (5)
- Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now (2011) (5)
- Postpartum disease activity and breastfeeding in multiple sclerosis revisited (2010) (5)
- Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system (2015) (5)
- 4-Aminopyridin (Fampridin) (2010) (5)
- Quinpramine--a promising compound for treating immune-mediated demyelination of the nervous system. (2010) (5)
- Immune-mediated neuropathies. (2002) (5)
- Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study (2021) (5)
- Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. (2012) (5)
- Multiple sclerosis: Combination therapy in MS—still a valid strategy (2011) (5)
- Treosulfan impedes the migration of immunocompetent cells (2007) (4)
- New evidence for teriflunomide in multiple sclerosis (2014) (4)
- INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS (2009) (4)
- Asymptomatic reactivation of JC virus in patients treated with natalizumab. (2009) (4)
- [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies]. (2009) (4)
- Alemtuzumab (2014) (4)
- Alteration of the cytokine signature by various TLR ligands in different T cell populations in MOG37-50 and MOG35-55-induced EAE in C57BL/6 mice. (2016) (4)
- The Biology of Schwann Cells: Schwann cells as immunomodulatory cells (2007) (4)
- [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. (2011) (4)
- Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia (2020) (4)
- [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis]. (2010) (4)
- [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis]. (2010) (4)
- Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy (2014) (4)
- Serum Neurofilament Light (NfL): Towards a Blood Test for Prognosis and Disease/Treatment Monitoring in Multiple Sclerosis Patients (S24.003) (2018) (4)
- Multiple Sclerosis Decision Model (MSDM): A Multifactorial Model To Monitor Treatment Response And Disease Course In Relapsing Remitting Multiple Sclerosis (P3.133) (2014) (3)
- [Acute and chronic inflammatory neuropathies--diagnosis]. (2003) (3)
- Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis (2012) (3)
- [Current aspects of therapy conversion for multiple sclerosis]. (2015) (3)
- Long-term TherapyWith Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica SpectrumDisorder (2015) (3)
- The pentapeptide QYNAD does not inhibit neuronal network activity. (2005) (3)
- Transforming multiple sclerosis trials into practical reality (2011) (3)
- The challenges of measuring disability accumulation in relapsing–remitting multiple sclerosis: evidence from interferon beta treatments (2014) (3)
- Correction: Promoting Myelination in an In Vitro Mouse Model of the Peripheral Nervous System: The Effect of Wine Ingredients (2013) (3)
- Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis. (2014) (3)
- The prefaces of Charcot: Leitmotifs of an international career (2003) (3)
- Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Who Were Treatment-Naive or Who Relapsed on Prior Therapy (P2.209) (2014) (3)
- Multiple sclerosis: advances, excitements, disenchantments (2006) (3)
- [Blocking adhesion molecules with natalizumab in multiple sclerosis]. (2005) (3)
- [Statins for treatment of CNS diseases. Status report from research and clinical practice]. (2005) (3)
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
- Chapter 25 – Introduction to Immune Reactions in the Peripheral Nervous System (2005) (2)
- Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (I7-1.002) (2014) (2)
- The metalloproteinase‐disintegrin ADAM10 is exclusively expressed by type I muscle fibers (2008) (2)
- The Pentapeptide QYNAD Does Not Inhibit Neuronal Network Activity (2005) (2)
- Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’ (2016) (2)
- [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. (2004) (2)
- [New understanding of the immunopathogenesis of multiple sclerosis]. (2003) (2)
- Regulatory T cells in myositis — Good Samaritans at the site of inflammation? (2010) (2)
- Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system. (2000) (2)
- Cannabinoids in multiple sclerosis. Opportunity or threat (2004) (2)
- Cellular composition of peripheral blood mononuclear cells during 4 years long-term treatment with fingolimod (P5.364) (2017) (2)
- Bioavailability of Interferon‐beta in patients with multiple sclerosis – fishing for the surrogate (2010) (2)
- Multiple sclerosis ‐ a dynamic field with a need for excellent education (2015) (2)
- The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) patient cohort (P4.381) (2018) (2)
- [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy]. (2009) (2)
- Targeting lysophospholipid signaling as a therapeutic approach towards improved peripheral nerve regeneration (2016) (2)
- Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005) (2014) (2)
- Predicting treatment responses to IV immunoglobulins (2009) (2)
- Progress in Recognizing and Treating Polyneuropathy. (2018) (1)
- Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis (2014) (1)
- The sphingosine-1-phosphate receptor agonist FTY720 promotes peripheral nerve regeneration (2014) (1)
- [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]. (2007) (1)
- Therapeutic plasma exchange in multifocal motor neuropathy (2007) (1)
- Observational Program Tysabri 24 Plus: Evaluating Efficacy and Safety of Natalizumab Therapy beyond Two Years (P01.161) (2013) (1)
- [Jean-Martin Charcot in German neurology]. (2004) (1)
- Interleukin-17 impedes Schwann cell-mediated myelination (2014) (1)
- The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy. (1999) (1)
- Defining the new end point for multiple sclerosis treatment. (2014) (1)
- Immune mechanisms in neurological disease (2002) (1)
- The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis (2013) (1)
- [Interferon β for multiple sclerosis. How much is good enough?]. (2010) (1)
- Autonomic dysfunction in Guillain-Barré syndrome: circulating IgG alter noradrenaline synthesis in sympathetic neurons (2009) (1)
- Immunomodulation in multiple sclerosis (2011) (1)
- [Teriflunomide for treatment of multiple sclerosis]. (2013) (1)
- NK cell markers predict the efficacy of IV immunoglobulins in CIDP (2020) (1)
- Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™ (2014) (1)
- Peginterferon Beta-1a is Effective as Early as Twelve Weeks Following Treatment Initiation in Patients With Relapsing Multiple Sclerosis (S4.001) (2015) (1)
- Pegyliertes Interferon-beta 1a (2015) (1)
- Predicting multiple sclerosis: a large international multicentre study (2015) (1)
- Multiple Sklerose – Revision der neuen McDonald-Diagnosekriterien (2006) (1)
- Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies (2012) (1)
- [Multiple sclerosis: potential therapeutic options and update of ongoing studies]. (2004) (1)
- Effect of Ofatumumab on Pregnancy, Parturition and Lactation in Cynomolgus Monkeys. (2021) (1)
- Heat exposure and bicycling trigger recurrent aseptic meningitis: a case report (2014) (1)
- Schwann cell locomotion during peripheral nerve inflammation (2014) (1)
- Proteases in CNS Infection and Inflammation (2005) (1)
- [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]. (2009) (1)
- [Acute and chronic inflammatory neuropathies--therapy]. (2003) (0)
- Remibrutinib Inhibits Neuroinflammation Driven by B Cells and Myeloid Cells in Preclinical Models of Multiple Sclerosis (P2-3.013) (2023) (0)
- EPO reduces the inflammatory profile of macrophages in vitro . (2013) (0)
- Clinical consequences of persistently high-titer neutralizing antibodies in patients with multiple sclerosis — /INS;Results from the German reference lab (2013) (0)
- EP 41. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathies (2016) (0)
- Remibrutinib, a Novel Bruton’s Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency In Vitro (P8-3.003) (2023) (0)
- Natalizumab Increases Circulating CD34+ Cells with An Impaired Functional Potential In Patients with Multiple Sclerosis without Affecting the Bone Marrow. (2010) (0)
- [Plasma exchange as a therapeutic option in neurological disorders]. (2007) (0)
- Analysis of Peripheral Blood Mononuclear Cell Phenotypes during Treatment with Fingolimod: A 2-Year Study of a German Cohort of Patients with Relapsing-Remitting Multiple Sclerosis (P3.097) (2016) (0)
- Correlation of fingolimod induced lymphopenia and physical measures in MS patients (2014) (0)
- Peginterferon Beta-1a Significantly Increases the Proportion of Patients with Freedom from Measured Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the ADVANCE Study (S4.007) (2014) (0)
- [Mitoxanthrone in the therapy of multiple sclerosis]. (2003) (0)
- Subgroup and Sensitivity Analyses of the Primary Endpoint from the Peginterferon Beta-1a ADVANCE Study: A Pivotal Phase 3 Study in Patients with Relapsing-Remitting Multiple Sclerosis (P3.169) (2014) (0)
- Trapped in the epineurium: early entry into the endoneurium is restricted to neuritogenic T cells in experimental autoimmune neuritis (2018) (0)
- Axons are the primary targets of nitric oxide mediated injury in an in vitro model of inflammatory neuropathy (2007) (0)
- TLR 3 ligand poly I:C does not induce encephalitogenic T cells nor essentially alter cytokine production in SJL EAE (2013) (0)
- Web figure 1 (2013) (0)
- Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II (2017) (0)
- PREGNANCY OUTCOMES FROM TERIFLUNOMIDE CLINICAL STUDIES (2014) (0)
- Novel pathomechanisms in inflammatory neuropathies (2017) (0)
- Experimental Autoimmune Encephalomyelitis (2003) (0)
- Multiple Sklerose – Neue Therapieoptionen (2011) (0)
- Regulatory T Cells Determine Disease Severity in Experimental Autoimmune Neuropathies (IN1-1.006) (2012) (0)
- 018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab (2022) (0)
- [Choice of early and escalation treatment options for multiple sclerosis]. (2008) (0)
- Effect of intravenous immunoglobulins on natural killer cells (2014) (0)
- ADVANCE Results: PEG-IFN- -1a Decreases Disability in RRMS (2014) (0)
- Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
- The Efficacy of Peginterferon Beta-1a in Early and Later-Stage Patients With Multiple Sclerosis: A 1-Year Subgroup Analysis Based on Disease Duration from the ADVANCE Study (P7.267) (2015) (0)
- Mitoxantrone as rescue therapy in two children with worsening multiple sclerosis (2005) (0)
- Multiple sclerosis patients concurrently treated with disease-modifying therapies show clinically meaningful increases in walking speed with prolonged-release fampridine (2011) (0)
- Immunological parameters in blood as surrogate markers in multiple sclerosis (2001) (0)
- Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial (2022) (0)
- EP 12. Fingolimod promotes nerve regeneration by modulating Lysophospholipid signaling (2016) (0)
- Effects of different anti-ganglioside antibodies on nerve regeneration in vitro (2005) (0)
- [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis]. (2015) (0)
- NK Cells as Surrogate Marker for Predicting Treatment Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy (2019) (0)
- Oral tolerance induction in experimental autoimmune encephalomyelitis with Candida expressing a specific Mog peptide (2014) (0)
- First results of a prospective cohort study in clinically isolated syndromes and early multiple sclerosis of the German Competence Network Multiple Sclerosis (2015) (0)
- Advances in biotechnology and novel insights into pathophysiology have contributed to an increased understanding of the pathomechanisms of diseases affecting the peripheral nervous system. (2008) (0)
- Natalizumab long-term therapy for relapsing MS in clinical routine: Final results of the prospective observational multicenter study Tysabri® 24 plus (2013) (0)
- Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic Regulation (S37.006) (2016) (0)
- Monocyte-derived HLA-G, a strong inhibitor of autologous CD4 T-cell activation, is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis? (2004) (0)
- Immunomodulatory Potential of Anti-IFN-Beta Antibodies on Monocyte Derived Macrophages (2023) (0)
- Alemtuzumab: Current Concepts and Application for the Treatment of Multiple Sclerosis (2012) (0)
- The Role of Peripheral Myelin Protein 2 in Remyelination (2017) (0)
- Pharmacotherapy Options for Multiple Sclerosis: Focus on Natalizumab (2010) (0)
- Matrix metalloproteinases in experimental autoimmune encephalomyelitis. (1997) (0)
- Vitamin D and Immunogenicity of IFNβ in Multiple Sclerosis Patients: A Case-Control Study (P3.355) (2016) (0)
- Response to Mousavizadeh et al.: Oxidative toxicity and glutamate excitotoxicity in multiple sclerosis (2003) (0)
- Clinical Consequences of Persistently High-Titer Neutralizing Antibodies in Patients with Multiple Sclerosis – Results from the German Reference Lab (P01.192) (2013) (0)
- Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling (2016) (0)
- Phenotypes of Peripheral Blood Mononuclear Cells and Immunoglobulin Analysis under Treatment with Fingolimod: A Prospective Study (P05.152) (2013) (0)
- Schwann cells as conditional antigen presenting cells in inflammatory neuropathies (2007) (0)
- Preferential Entrapment of Naive T Cells Associates with a Less Diverse T Cell Receptor Repertoire in MS Patients Treated with Fingolimod (P5.296) (2016) (0)
- Positives CHMP-Votum (2015) (0)
- Efficacy of Fingolimod Therapy Does Not Dependent on the Individual Body Mass Index in Patients with MS (P7.223) (2014) (0)
- Options for Multiple sclerosis : Focus on natalizumab (2010) (0)
- [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies]. (2013) (0)
- Treatment of Neurological Autoimmune Disorders with Rituximab – A 7 Years Single Center Experience (P04.140) (2012) (0)
- Metalloproteinases as mediators of tissue regeneration in the peripheral nerve: an important role for metalloproteinase-2 (2007) (0)
- Chemokines in the Inflamed Peripheral Nervous System (2002) (0)
- [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators]. (2003) (0)
- Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015) (2023) (0)
- POLG mutations had a mixed axonal-demyelinating type of sensory neuropathy. Discussion. External ophthalmoplegia and (in par- ticular axonal) sensory neuropathy are highly sugges- tive of underlying POLG mutations in patients with cerebellar ataxia in which common SCA and FRDA (2009) (0)
- The Effect of Fingolimod on Peripheral Blood Mononuclear Cell Phenotypes: A Prospective Study (P02.122) (2012) (0)
- [Matrix metalloproteinases. Potential targets for new treatments in inflammatory demyelinating diseases of the nervous system]. (1999) (0)
- Therapy With Interferon-Beta Has No Impact On The T Cell Receptor Repertoire in MS Patients (P1.200) (2014) (0)
- Neuro Performance Testing as an Alternative to EDSS for Measuring Multiple Sclerosis Disability Progression in Clinical Practice (P2.118) (2016) (0)
- Currently Approved Disease-Modifying Drugs (2016) (0)
- Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy (2021) (0)
- Peripheral Nervous System, Immunology of (2003) (0)
- Different expression patterns of matrix metalloproteinases in inflammatory demyelinating diseases of the central and peripheral nervous system (1998) (0)
- Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice (S9.007) (2023) (0)
- Immunopathogenesis of Multiple Sclerosis: Overview (2007) (0)
- Translating new insights into treatment optimisation in multiple sclerosis (2009) (0)
- 2PS2.3 New treatments for autoimmune disorders (2011) (0)
- O20: NK Cells as Surrogate Marker for Predicting Treatment Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy (2018) (0)
- An Interesting Case of Nuchal Rigidity (2011) (0)
- Interferon β bei Multipler Sklerose (2010) (0)
- the Dysfunctional Immune Regulation in Plasmacytoid Dendritic Cells Characterizes Phenotypically Different Subsets of An Imbalance of Two Functionally and (2017) (0)
- Exome Array GWAS in 10,000 Germans Identifies Association between MUC22 and Multiple Sclerosis (2015) (0)
- In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses (P7.256) (2015) (0)
- Guillain–Barré Syndrome, Neuroimmunology of (2003) (0)
- Metalloproteinase-Disintegrins in MS Patients and Their Regulation by Interferon-beta (P02.074) (2012) (0)
- [Alemtuzumab: a further option for treatment of multiple sclerosis]. (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Bernd C. Kieseier?
Bernd C. Kieseier is affiliated with the following schools:
